Peer-reviewed veterinary case report
New treatment using miltefosine micelles for visceral leishmaniasis
By Alizadeh, Zahra et al.·Published in Research in veterinary science·2025·Department of Medical Parasitology and Mycology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Formulation, in vitro evaluation and therapeutic effect of chitosan coated pluronic F127 micelles containing miltefosine for the treatment of visceral leishmaniasis in domestic dogs naturally infected by Leishmania infantum.
- Species:
- dog
Plain-English summary
A group of dogs naturally infected with Leishmania infantum, which causes visceral leishmaniasis, received a new treatment involving chitosan-coated micelles containing miltefosine. This innovative formulation was tested to see if it could be more effective than miltefosine alone. The dogs tolerated the treatment well, receiving daily injections for 28 days, and the new formulation showed better results in fighting the infection compared to the standard treatment. This could be a promising option for dogs suffering from this serious disease.
People also search for: dog leishmaniasis treatment · miltefosine for dogs · chitosan micelles for dog infections
Abstract
There are a limited number of chemotherapeutic agents for the treatment canine visceral leishmaniasis (CVL). This study aimed to formulate and assess micellar formulation of miltefosine (MTF) to increase antileishmanial therapeutic effects in dogs naturally infected by Leishmania (L) infantum for the first time. MTF loaded pluronic F127 (PF/MTF) micelles were formulated and coated with chitosan (Cs/PF/MTF). Toxicity of compounds was evaluated. The in vitro and in vivo antileishmanial effect of Cs/PF/MTF was examined in L. infantum promastigotes and amastigotes as well as naturally infected dogs by L. infantum. In-vitro efficacy studies in promastigotes and amastigotes demonstrated that inhibitory concentration (IC50) of Cs/PF/MTF was significantly lower in comparison to miltefosine. In vivo data showed that Cs/PF/MTF is more effective against CVL compared with miltefosine alone. The result of this study indicated that intravenous injection of new formulation of Cs/PF/MTF was tolerated and treated on L. infantum naturally infected dogs with the dosages of 170 μg/kg daily for 28 days.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39591859/